Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06311851
PHASE1/PHASE2

Transarterial Chemoembolization (TACE) Plus Bevacizumab for Liver Metastases

Sponsor: Pardis Noor Medical Imaging and Cancer Center

View on ClinicalTrials.gov

Summary

Trans arterial chemoembolization (TACE) has emerged as a treatment option for chemotherapy-refractory diseases in Liver metastases. By delivering chemotherapy agents directly to the tumor site, TACE can maximize local drug concentrations and reduce systemic adverse reactions. Bevacizumab is a monoclonal antibody that functions as an angiogenesis inhibitor. It works by slowing the growth of new blood vessels by inhibiting vascular endothelial growth factor A (VEGF-A). The application of Bevacizumab during TACE has not been reported. In this study, we will evaluate the the overall survival (OS)、efficacy, and safety of the application of Bevacizumab during TACE in patients with Liver Metastases by designing an open, single-arm phase II clinical study.

Official title: An Open-Label Pilot Study to Evaluate Efficacy and Safety of Bevacizumab Via Transarterial Chemoembolization (TACE) in Patients With Liver Metastases

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

40

Start Date

2025-06-01

Completion Date

2026-04-30

Last Updated

2025-11-25

Healthy Volunteers

No

Interventions

DRUG

Bevacizumab

Infusion of Bevacizumab-loaded hepaspher through transarterial chemoembolization.

Locations (1)

Pardis Noor Medical Imaging and Cancer Center

Tehran, Tehran Province, Iran